Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis
Journal of Controlled Release · 2026-04 · 392 · 114697
DOI: 10.1016/j.jconrel.2026.114697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-04. Verfasst von Bihui Cao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guang…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Gelatinases, Hydrogels, Myocardial Infarction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, Universidade de Macau, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Cardiac fibrosis is a key pathological feature of both acute and chronic heart diseases, characterized by abnormal accumulation of extracellular matrix resulting from fibroblast activation. Although fibroblast activation protein (FAP)-targeted chimeric antigen receptor (CAR) T cell therapy has shown promise in selectively eliminating activated fibroblasts, systemic administration remains limited by off-target toxicity and insufficient trafficking to the diseased myocardium. Here, we present a reactive oxygen species (ROS)-responsive hydrogel designed for intrapericardial delivery of FAP-specific CAR-T (FAP-CAR-T) cells to locally treat post-myocardial infarction (MI) fibrosis. This hydrogel, based on a thioketal-crosslinked polyethylene glycol matrix, selectively degrades in the ROS-enriched microenvironment of fibrotic tissue, enabling the controlled release of encapsulated FAP-CAR-T cells. In vitro, FAP-CAR-T cells exhibited antigen-dependent cytotoxicity against FAP+ targets, and hydrogel-encapsulated CAR-T cells maintained robust proliferation and showed ROS-triggered release kinetics. Using murine models of MI-induced fibrosis, the hydrogel-based intrapericardial delivery strategy enhanced FAP-CAR-T cells infiltration, persistence, and effector function, resulting in significant depletion of activated fibroblasts, attenuation of fibrotic remodeling, and preservation of cardiac structure and left ventricular function. This hydrogel-based CAR-T immunotherapeutic platform provides a localized, targeted, and on-demand strategy for combating cardiac fibrosis and may offer broader translational potential for the treatment of fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510100, China; Guangdong Provincial Key Laboratory of Pathogenesi…
- Department of Radiology, Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China.
- MoE Frontiers Science Center for Precision Oncology, Faculty of Health Sciences, University of Macau, Macau, SAR 999078, China.
- Nanomedicine Research Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China.
Förderung
- Science and Technology Planning Project of Guangdong Province
- Universidade de Macau
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
- Guangdong Provincial People's Hospital
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Cao, B., Liu, M., Anwaier, S., Long, X., You, T., He, Z., Su, H., Zhang, X., Wang, J., Huang, H., Liu, N., Jiang, Y., Xiang, H., Assaraf, Y. G., Zhu, X., Ma, X., Zhao, Q., Zhu, P., & Wang, L. (2026). Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis. Journal of Controlled Release, 392, 114697. https://doi.org/10.1016/j.jconrel.2026.114697
Vancouver
Cao B, Liu M, Anwaier S, Long X, You T, He Z, et al. Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis. Journal of Controlled Release. 2026;392:114697. doi:10.1016/j.jconrel.2026.114697
BibTeX
@article{Cao2026,
author = {Cao, Bihui and Liu, Manting and Anwaier, Sainiwaer and Long, Xiang and You, Ting and He, Zijian and Su, Haotao and Zhang, Xinkui and Wang, Jiaqi and Huang, Huanlei and Liu, Nanbo and Jiang, Yujie and Xiang, Hongmo and Assaraf, Yehuda G and Zhu, Xiaolan and Ma, Xuelei and Zhao, Qi and Zhu, Ping and Wang, Lu},
title = {Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis},
journal = {Journal of Controlled Release},
year = {2026},
volume = {392},
pages = {114697},
doi = {10.1016/j.jconrel.2026.114697}
}
EUVIMED